RVO

Latest News

FDA extends target action date for two Regeneron regulatory submissions to Q4 of 2025
FDA extends target action date for two Regeneron regulatory submissions to Q4 of 2025

August 27th 2025

Included is the supplemental Biologics License Application (sBLA) for EYLEA HD seeking approval for both the treatment of macular edema following retinal vein occlusion (RVO) and the broadening of the dosing schedule to include every 4-week dosing across approved indications.

UK MHRA approves phase 2a study for ANXV for diabetic retinopathy
UK MHRA approves phase 2a study for ANXV for diabetic retinopathy

August 22nd 2025

Lupin and Sandoz sign licensing deal for biosimilar ranibizumab across multiple regions
Lupin and Sandoz sign licensing deal for biosimilar ranibizumab across multiple regions

August 14th 2025

Optigo Bio receives People’s Choice Award for its proprietary drug anchoring
Optigo Bio receives People’s Choice Award for its proprietary drug anchoring

May 9th 2025

FDA issues CRL for Regeneron's aflibercept 8 mg (Eylea HD) sBLA
FDA issues CRL for Regeneron's aflibercept 8 mg (Eylea HD) sBLA

April 21st 2025

More News

Image Credit: ©pressmaster - stock.adobe.com

Genentech seeks indication for faricimab-svoa from the FDA for retinal vein inclusion (RVO)

Kassi Jackson
May 11th 2023

If approved, RVO would be the third indication for faricimab-svoa in addition to wet age-related macular degeneration (AMD) and diabetic macular edema (DME).

© myskin / stock.adobe.com

Study determines retinal vein occlusion after COVID-19 vaccinations to be rare

Lynda Charters
April 17th 2023

A large cohort study found no association between the first messenger RNA COVID-19 vaccinations and acute retinal vein occlusions.

<12
© 2025 MJH Life Sciences

All rights reserved.